Global Fragment Based Drug Discovery Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Global Fragment Based Drug Discovery Market is Segmented By Component (Biophysical Techniques (NMR Spectroscopy, Differential Scanning Fluorimetry (DSF) Assay, Fluorescence Polarization, Isothermal Titration Calorimetry, X-ray Crystallography, Surface Plasmon Resonance (SPR), Bilayer Interferometry, Mass Spectrometry (MS), Capillary Electrophoresis, Weak Affinity Chromatography (WAC - HPLCUV/MS), Other assays (biochemical)), Non-biophysical Techniques), By Application (Oncology, Central Nervous System (CNS) Disorders, Infectious Diseases, Cardiovascular Diseases, Metabolic Disorders, Inflammation & Autoimmune Diseases), By End-user (Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.

Global Fragment Based Drug Discovery Market is Segmented By Component (Biophysical Techniques (NMR Spectroscopy, Differential Scanning Fluorimetry (DS....

Competitive overview of Global Fragment Based Drug Discovery Market

The major players operating in the Global Fragment Based Drug Discovery Market include Emerald BioStructures, Inc., Crown Bioscience, Vernalis Research, Sygnature Discovery, Shanghai ChemPartner, SARomics Biostructures, Red Glead Discovery, Domainex, CRELUX, ComInnex, Creative Biolabs, ChemAxon, 2bind, Amgen and University of California, San Francisco.